« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Print This Page

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 33

87% CHADS2 ≥3

An important characteristic of the ROCKET AF trial.[97] in distinction from the RE-LY trial,[96] was that the mean CHADS₂ score was higher (3.5) for both the rivaroxaban and warfarin arms. As a result, approximately 90% of the patients had a history of prior CNS embolism -- so re-emphasizing that the ROCKET AF population was a very sick group of patients.

Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[96] Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

[97] Patel MR, Mahaffey KW, Garg J, et al; the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.